MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.40
+0.22
+2.69%
Opening 14:42 11/22 EST
OPEN
8.05
PREV CLOSE
8.18
HIGH
8.50
LOW
7.50
VOLUME
351.89K
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
5.49
MARKET CAP
403.23M
P/E (TTM)
-5.8770
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PRQR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PRQR News

  • ProQR shares rises on FDA orphan drug designation
  • MarketWatch.1d ago
  • ProQR Therapeutics on watch after FDA win
  • Seeking Alpha - Article.1d ago
  • ProQR Therapeutics Reports Received Orphan Drug Designation For QR-1123 For Autosomal Dominant Retinitis Pigmentosa
  • Benzinga.1d ago
  • ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
  • GlobeNewswire.1d ago

More

Industry

Biotechnology & Medical Research
+1.70%
Pharmaceuticals & Medical Research
+0.77%

Hot Stocks

Name
Price
%Change

About PRQR

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More

Webull offers ProQR Therapeutics NV (PRQR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.